In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender

Neuroendocrinology Letters

Volumn 28, Issue 5, 2007, Pages 621-628

  Zgliczynski, Wojciech ^a   Kochman, Magdalena ^a   Misiorowski, Waldemar ^a   Zdunowski, Piotr ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Acromegaly; Bone metabolism; Bone mineral density; Growth hormone; Hypogonadism; Osteocalcin; Type I collagen carboxyterminal telopeptide

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; ESTRADIOL; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; OSTEOCALCIN; PROLACTIN; SOMATOMEDIN C; TESTOSTERONE;

ACROMEGALY; ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; CORRELATION ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; FEMALE; FEMUR NECK; FOLLITROPIN BLOOD LEVEL; GONAD FUNCTION; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOGONADISM; LUMBAR SPINE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PROLACTIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; TESTOSTERONE BLOOD LEVEL;

EID: 38049133951     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bolanowski M, Jedrzejuk D, Milewicz A, Arkowska A (2002). Quantitative ultrasound of the heel and some parameters of bone turnover in patients with acromegaly. Osteoporos Int. 13: 303-308.
2. Bolanowski M, Daroszewski J, Zatonska K, Arkowska A (2006a). Circulating cytokines in relation to bone mineral density changes in patients with acromegaly. Neuro Endocrinoi Lett. 27(1-2): 183-188.
3. Bolanowski M, Zatonska K, Kaluzny M, Zielinski G, Bednarek-Tupikowska G, Bohdanowicz-Pawlak A, Daroszewski J, Szymczak J, Podgorski JK (2006b). A follow-up of 130 patients with acromegaly in a single centre. Neuro Endocrinol Lett. 27(6): 828-832
4. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA (1997) Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab. 82: 550-555.
5. De la Piedra C, Carbó E, Larrañaga J, Castro N, Horcajada C, Rapado A et al. (1988). Correlation among plasma osteocalcin, growth hormone and somatomedin C in acromegaly. Calcif Tissue Int. 43: 44-45.
6. Diamond T, Nery L, Posen S (1989). Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med. 111: 567-573.
7. Ezzat 5, Melmed S, Endres D, Eyre DR, Singer FR (1993). Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab. 76: 1452-1457.
8. Friend KE, Hartman ML, Pezzoli SS, Clasey JL, Thorner MO (1996). Both oral and transdermal estrogen increase growth hormone release in postmenopausal women - a clinical research center study. J Clin Endocrinol Metab. 81: 2250-2256.
9. Giustina A, Barkan A, Cassanueva FF, Cavaghini F, Frohman L, Ho K et al. (2000). Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 85: 526-529.
10. Halse J, Gordeladze JO (1981). Total and non-dialyzable urinary hydroxyproline in acromegalics and control subjects. Acta Endocrinol (Copenh). 96: 451-457.
11. Ho KK, Weissberger AJ (1992). Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism. J Bone Miner Res. 7: 821-827.
12. Ho KK, O'Sullivan AJ, Weissberger AJ, Kelly JJ (1996). Sex steroid regulation of growth hormone secretion and action. Horm Res. 45: 67-73.
13. Ho PJ, Fig LM, Barkan AL, Shapiro B (1992). Bone mineral density of the axial skeleton in acromegaly. J Nucl Med 33: 1608-1612.
14. Inzucchi SE, Robbins RJ (1994). Effects of growth hormone on human bone biology. J Clin Endocrinol Metab. 79: 691-694.
15. Jaworski M, Wyszomirski T, Biliński P, Czerwiński E, Lewiński A, Marcinowska-Suchowierska E et al. (2002). Bone mineral density measurements in adult Polish population - the EPOLOS study. Acta Orthop Scandinov. 73(suppl.304): 58.
16. Johansson AG, Engström BE, Ljunghall S, Karlsson PA, Burman P (1999). Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. J Clin Endocrinol Metab. 84: 2002-2007.
17. Kaji H, Sugimoto T, Nakaoka D, Okimura Y, Kaji H, Abe H et al. (2001). Bone metabolism and body composition in Japanese patients with active acromegaly. Clin Endocrinol (Oxf). 51: 175-181.
18. Kaltsas GA, Mukherjee JJ, Jenkins PJ, Satta MA, Islam N, Monson JP et al. (1999). Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab. 84: 2731-2735.
19. Katznelson L, Kleinberg D, Vance ML, Stravou S, Pulaski KJ, Schoenfeld DA et al. (2001). Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf). 54: 183-188.
20. Kayath MJ, Vieira JGH (1997). Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int. 7: 226-230.
21. Kochański J, Badurski JE (2002). Analiza 77776 wyników badań masy kostnej kuracjuszy w siedmiu polskich uzdrowiskach. Postepy Osteoartrologii. 13: 39-43.
22. Kotzmann H, Bernecker P, H?übsch P, Pietschmann P, Wołoszczuk W, Svoboda T et al. (1993). Bone mineral density and parameters of bone metabolism in patients with acromegaly. J Bone Miner Res. 8: 459-465.
23. Lesse GP, Fraser WD, Fraquharson R, Hipkin L, Vora JP (1998). Gonadal status is an important determinant of bone density in acromegaly. Clin Endocrinol (Oxf). 48: 59-65.
24. Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA et al. (2004). Official positions of the International Society for Clinical Densitometry. J Clin Endocrinol Metab. 89: 3651-3655.
25. Longobardi S, Di Somma C, Di Rella F, Angelillo N, Ferone D, Colao A et al. (1998). Bone mineral density and circulating cytokines in patients with acromegaly. J Endocrinol Invest. 21: 688-693.
26. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP (1998). Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 8: 468-489.
27. Marazuela M, Astigarraga B, Tabuenca MJ, Estrada J, Marin F, Lucas T (1993). Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int. 52: 419-421.
28. Nowak NA, Badurski JE, Supronik J, Dobreńko A, Lis J, Daniluk S et al. (2003). Epidemiologia osteoporozy u kobiet w aglomeracji Białegostoku (BOS). 1: Gestość kości a złamania. Postepy Osteoartrologii. 14: 1-5.
29. Ohlsson C, Bengtsson B-Å, Isaksson OGP, Andreassen TT, Slootweg MC (1998). Growth hormone and bone. Endocr Rev. 19: 55-79.
30. Piovesan A, Terzolo M, Reimondo G, Pia A, Codegone A, Osella G et al. (1994). Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome. Horm Metab Res. 26: 234-237.
31. Sandstedt J, Törnell J, Norjavaara E, Isaksson OGP, Ohlsson C (1996a). Intact testis function is a prerequisite for an optimal effect of elevated GH levels on vertebral bone weight in mice. Endocrinol Metab. (Suppl 1A) 4: 10.
32. Sandstedt J, Törnell J, Norjavaara E, Isaksson OGP, Ohlsson C (1996b). Elevated levels of growth hormone increase bone mineral content in normal young mice, but not in ovariectomized mice. Endocrinology. 137: 3368-3374.
33. Scillitani A, Chiodini I, Carnevale V, Giannatempo GM, Frusciante V, Villella M et al. (1997). Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. J Bone Miner Res. 12: 1729-1736.
34. Scillitani A, Battista C, Chiodini I, Carnevale V, Fusilli S, Ciccarelli E et al. (2003). Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status. Clin Endocrinol (Oxf). 58: 725-731.
35. Seeman E, Wahner HW, Offord KP, Kumar R, Johnson WJ, Riggs BL (1982). Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest. 69: 1302-1309.
36. Slootweg MC, Swolin D, Netelenbos JC, Isaksson OGP, Ohlsson C (1997). Estrogen enhances growth hormone receptor expression and growth hormone action in rat osteosarcoma cell and human osteoblast-like cells. J Endocrinol. 155: 159-164.
37. Terzolo M, Piovesan A, Ossela G, Pia A, Reimondo G, Pozzi C et al. (1993). Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effect of long-term octreoticle treatment. Calcif Tissue Int. 52: 188-191.
38. Thorner MO, Vance ML, Horvath E, Kovacs K (1992). The anterior pituitary. In: Wilson JD, Foster DW, editors. Williams textbook of endocrinology. 8th ed. Philadelphia: WB Saunders Company. p. 221-310.
39. Tütüncü NB, Erbaş T (2004). Factors associated with bone metabolism in acromegalic patients: hypogonadism and female gender. Exp Clin Endocrinol Diabetes. 112: 328-332.
40. Ueland T, Bollerslev J, Godang K, Müller F, Frøland SS, Aukrust P (2001). Incerased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess - possible role in bone homeostasis. Eur J Endocrinol. 145: 685-690.
41. Vestergaard P, Mosekilde L (2004). Fracture risk is decreased in acromegaly - a potential beneficial effect of growth hormone. Osteoporos Int. 15: 155-159.